Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ocean Biomedical, Inc. Market Cap
From what 0 stock analysts predict, the share price for Ocean Biomedical, Inc. (OCEA) might increase by 1932.97% in the next year. This is based on a 12-month average estimation for OCEA. Price targets go from $18.5 to $18.5. The majority of stock analysts believe OCEA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Ocean Biomedical, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Ocean Biomedical, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of OCEA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Howard Halpern Taglich Brothers | Speculative Buy | $20 | Initiates | May 31, 2023 |
| Tony Butler EF Hutton | Buy | $17 | Assumes | May 25, 2023 |
| Michael King EF Hutton | Buy | $17 | Maintains | Apr 27, 2023 |
| Michael King EF Hutton | Buy | $10 | Reiterates | Apr 13, 2023 |
| Sid Rajeev Fundamental Research Corp. | Buy | $16.4 | Initiates | Mar 16, 2023 |
| Michael King EF Hutton | Buy | $10 | Initiates | Mar 13, 2023 |
When did it IPO
2021
Staff Count
0
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Elizabeth Ng M.B.A.
Market Cap
$31.6M
In 2023, OCEA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that OCEA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 27 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocean Biomedical (NASDAQ: OCEA) announced a key U.S. patent for a malaria therapeutic antibody targeting PfGARP, potentially leading to new vaccines and treatments for malaria.
Why It Matters - Ocean Biomedical's patent for a malaria therapeutic could lead to significant advancements in treatment and prevention, potentially boosting revenue and market position, attracting investor interest.
Fri, 23 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocean Biomedical, Inc. (NASDAQ: OCEA) is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the failure to file its Quarterly Report on Form 10-Q for Q2 2024.
Why It Matters - Ocean Biomedical's non-compliance with Nasdaq's reporting requirement raises concerns about financial transparency and could lead to stock delisting, impacting investor confidence and stock value.
Thu, 22 Aug 2024
Sentiment - POSITIVE
Source - 24/7 Wall Street
Summary - Biotech stocks are highlighted as favorable investment opportunities due to their potential for growth and innovation in the healthcare sector.
Why It Matters - Biotech stocks often offer high growth potential and innovation opportunities, attracting investors seeking substantial returns in emerging health technologies.
Wed, 05 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocean Biomedical, Inc. (NASDAQ: OCEA) announced its partner Virion Therapeutics presented human immunogenicity data for VRON-0200, a novel HBV immunotherapy, at the EASL 2024 Congress in Milan.
Why It Matters - Ocean Biomedical's partnership with Virion Therapeutics showcases potential advancements in immunotherapy for HBV, signaling innovation and market opportunities that could impact stock performance.
Thu, 16 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocean Biomedical (NASDAQ: OCEA) announced a new patent granted to co-founder Dr. Jonathan Kurtis for a malaria therapeutic antibody, aimed at prevention and treatment amid rising drug resistance.
Why It Matters - Ocean Biomedical's new patent for a malaria therapeutic could position the company as a leader in addressing drug resistance, potentially increasing its market value and attracting investor interest.
Wed, 24 Apr 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocean Biomedical, Inc. (NASDAQ: OCEA) has been notified by Nasdaq of non-compliance with Listing Rule 5250(c)(1) due to the failure to file its Annual Report on Form 10-K for 2023.
Why It Matters - Ocean Biomedical's non-compliance with Nasdaq reporting requirements raises concerns about its financial transparency and stability, potentially impacting investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
